What’s the current market cap for ICON plc stock?

ICON plc (ICLR) has a market cap of $11B as of June 03, 2026.

What is the P/E ratio for ICON plc stock?

The price to earnings (P/E) ratio for ICON plc (ICLR) stock is 47.43 as of June 03, 2026.

Does ICON plc stock pay dividends?

No, ICON plc (ICLR) stock does not pay dividends to its shareholders as of June 03, 2026.

When is the next ICON plc dividend payment date?

ICON plc (ICLR) stock does not pay dividends to its shareholders.

What is the beta indicator for ICON plc?

ICON plc (ICLR) has a beta rating of 1.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy ICON plc stock | $ICLR Share Price

About ICON plc

Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.

Ticker

$ICLR

Sector

Health

Primary listing

NASDAQ

Employees

40,100

Headquarters

Dublin, Ireland

Website

www.iconplc.com

ICON plc Metrics

BasicAdvanced

$11bn

47.43

$2.90

1.23

-

What the Analysts think about ICON plc

Analyst ratings (Buy, Hold, Sell) for ICON plc stock.

Bulls say / Bears say

Completion of the internal audit investigation has removed a key overhang by confirming no material impact to operations or cash flow and limiting past revenue overstatements to under 2%, which should support valuation once uncertainty abates (Reuters)

The strategic partnership with Advarra to integrate ICON’s clinical trial technology with leading site systems is designed to reduce administrative friction, accelerate study startups, and enhance patient recruitment, potentially driving margin expansion and competitive differentiation (Business Wire)

Truist Securities’ reiteration of a Hold rating with a $139 price target implies roughly 20% upside from current levels, reflecting a view among analysts that ICON remains undervalued based on its P/E and fair value assessments (Reuters)

The February accounting investigation uncovered revenue recognition errors from 2023 through 2025, delayed Q4 2025 results, and raised the risk of material restatements, undermining confidence in ICON’s historical financial reporting (Reuters)

The contract research sector is experiencing slowing trial starts, heightened competition, and funding constraints, which are likely to weigh on ICON’s top-line growth and contract award momentum (Reuters)

ICON has seen one positive but five negative EPS revisions in the last 90 days, reflecting analysts’ downward adjustments amid ongoing operational uncertainties and suggesting potential for further earnings downgrades (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 13 May 2026.

ICON plc Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

ICON plc Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

ICON plc News

AllArticlesVideos

Icon Q4 Earnings Call Highlights

MarketBeat·6 days ago

ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation

Business Wire·7 days ago

ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq

Business Wire·1 week ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.